WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking place on October 25, 2018. Data from a Phase 3 clinical trial conducted with KPI-121 0.25% for the short-term treatment of dry eye disease and data from the Phase 3 clinical trials conducted with INVELTYS™ (loteprednol etabonate ophthalmic suspension) 1%, a twice-a-day topical ocular corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery, will also be presented at the 2018 American Academy of Ophthalmology (AAO) annual meeting taking place October 27-30, 2018 in Chicago, IL.
Details of the presentations are as follows:
Meeting: OIS@AAO
Session title: Company Showcase 2
Date:
Thursday, October 25, 2018
Time: 10:41 - 10:47 AM CT
Location:
Marriott Marquis Chicago
Presenter: Mark Iwicki,
Chairman and Chief Executive Officer of Kala Pharmaceuticals
Meeting: AAO
Title: KPI-121 0.25% for Short-term
Treatment of Dry Eye Disease: Results of a Multicenter Randomized Phase
3 Trial (STRIDE 1)
Date: Sunday, October 28, 2018
Time:
12:45 - 1:45 PM CT
Location: McCormick Place, Hall A
Presenter:
Preeya Gupta, M.D., Associate Professor of Ophthalmology, Duke
University School of Medicine
Meeting: AAO
Title: Phase 3 Results for KPI-121 1%
Ophthalmic Suspension Dosed BID Versus Placebo for the Treatment of
Ocular Inflammation and Pain Following Cataract Surgery
Date:
Monday, October 29, 2018
Time: 12:45 - 1:45 PM CT
Location:
McCormick Place, Hall A
Presenter: John Sheppard, M.D.,
MMSc, Program Director for Ophthalmology Residency Research, Clinical
Director for the Thomas R. Lee Center for Ocular Pharmacology, and
Professor of Ophthalmology, Microbiology & Molecular Biology, Eastern
Virginia Medical School; Medical Director of the Lions Medical Eye Bank
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. In preclinical studies, MPPs increased drug delivery into ocular tissues more than three-fold by facilitating penetration through the tear film mucus. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.
